Endocrine

Gender-affirming hormone therapy: monitoring and complications

Clinical Overview and When to Suspect Hormone-Related Issues in GAHT

— Feminizing regimen: estradiol (oral, transdermal, injectable) ± antiandrogen (spironolactone, GnRH agonist, or 5α-reductase inhibitor)

— Masculinizing regimen: testosterone (IM, SC, transdermal gel/patch); no antiestrogen needed

— Feminizing: estradiol ~100–200 pg/mL, testosterone <50 ng/dL

— Masculinizing: total testosterone 400–700 ng/dL (mid-normal male range)

— New unilateral leg swelling, chest pain, or dyspnea in a patient on estradiol → VTE/PE

— Polycythemia (Hct >54%) in a patient on testosterone

— Elevated prolactin, galactorrhea, headaches, visual changes on estradiol

— Hyperkalemia/hypotension in a patient on spironolactone

— Acne, hair loss, mood lability shortly after testosterone dose escalation

— Informed consent model is acceptable; comprehensive mental health evaluation no longer mandatory for adults

— Baseline labs required before initiation, then at 3, 6, 12 months, then every 6–12 months

Gender-affirming hormone therapy (GAHT) uses exogenous sex hormones to align secondary sex characteristics with gender identity in transgender and gender-diverse patients

Goals: achieve physiologic sex-hormone levels of the affirmed gender while minimizing adverse effects

When to suspect a GAHT-related complication on Step 3:

Endocrine Society and WPATH SOC-8 are the guideline anchors

Step 3 management: A 34-year-old transgender woman on oral estradiol 6 mg/day presents with calf pain — the correct move is D-dimer/ultrasound and transition from oral to transdermal estradiol, which has substantially lower VTE risk due to bypass of first-pass hepatic effects.

Board pearl: Risk of complications is dose-, route-, and duration-dependent — transdermal estradiol is preferred over oral in patients >40, smokers, or those with thrombophilia, migraine with aura, or cardiovascular risk.

Presentation Patterns and Key History

— Always ask about fertility preservation counseling before starting hormones (sperm banking, oocyte cryopreservation) — this is a documented requirement

— Feminizing GAHT: breast tenderness/growth (expected 3–6 months, maximal 2–3 years), decreased libido, erectile changes, softer skin, decreased muscle mass, mood changes, hot flashes if estradiol underdosed

— Masculinizing GAHT: voice deepening (permanent, 6–12 months), facial/body hair, clitoromegaly, amenorrhea (by 6 months), acne, increased libido, redistribution of fat

— Migraine with aura, prior VTE, hormone-sensitive cancer (breast, prostate), uncontrolled HTN, smoking, obesity → modify regimen

— Liver disease → avoid oral estradiol; use transdermal

— Cardiovascular disease → cautious testosterone titration, monitor lipids

Initial visit framework — establish gender identity, affirmed name/pronouns, prior hormone use (including non-prescribed/internet-sourced), surgical history, and reproductive goals

Symptom-driven presentations on monitoring visits:

Red-flag history points:

Persistent menses despite testosterone — common scenario; check trough testosterone level, ensure mid-normal male range; can add progestin or GnRH agonist if needed

Breakthrough bleeding after sustained amenorrhea on testosterone → workup for endometrial pathology, especially if >35 or risk factors

Key distinction: Expected vs pathologic symptoms — mild breast tenderness on estradiol is expected; unilateral breast mass or bloody nipple discharge is not and requires diagnostic imaging regardless of gender identity.

Step 3 management: Always document the organ inventory rather than assuming based on gender — a transgender man with a retained cervix still needs cervical cancer screening per USPSTF; a transgender woman with a retained prostate still warrants individualized prostate cancer screening discussion at age 55.

Board pearl: Ask about non-prescribed silicone or "pumping" injections in transfeminine patients — associated with embolism, granulomas, infection.

Physical Exam Findings and Vital Sign Assessment

— Blood pressure: estradiol may modestly lower BP; testosterone may raise BP — check at every visit, target <130/80

— Weight/BMI: testosterone increases lean mass; estradiol redistributes fat to hips/thighs — track trends

— Heart rate: tachycardia + tremor → consider hyperthyroidism (separate workup) vs supratherapeutic stimulant

— Tanner staging of breast development (expect Tanner 2–3 by 6 months, Tanner 4–5 by 2–3 years; if no growth by 18–24 months, reassess regimen)

— Decreased testicular volume, softer skin texture, decreased terminal body hair

— Gynecomastia asymmetry or masses warrant ultrasound

— Facial/body hair growth (Ferriman-Gallwey trends), male-pattern scalp hair loss

— Clitoromegaly (expected); voice deepening assessed by listening

— Acne distribution (face, back, chest) — grade severity

— Unilateral lower extremity edema/calf tenderness on estradiol → DVT workup

— Tachycardia, hypoxia, pleuritic pain → PE

— Severe hypertension on testosterone → check for erythrocytosis-driven hyperviscosity

— Vaginal atrophy from testosterone is common — use pediatric speculum, topical estrogen if needed

— Pap smears have higher inadequate-sample rates; counsel and consider self-collection HPV when available

General approach — perform an anatomically inclusive exam based on organs present, not gender presentation; use trauma-informed techniques and explicit consent before sensitive exams

Vital signs:

Feminizing GAHT exam findings:

Masculinizing GAHT exam findings:

Hemodynamic red flags:

Pelvic exam considerations in transmasculine patients:

CCS pearl: On a CCS case, order BP, HR, weight at every GAHT follow-up and document Tanner staging or virilization milestones — these count as appropriate monitoring actions.

Board pearl: Unilateral gynecomastia or breast lump in a transfeminine patient on estradiol = imaging required, not reassurance.

Diagnostic Workup — Initial Labs and Baseline Monitoring

— CBC (baseline Hct/Hgb — critical before testosterone)

— CMP (LFTs, renal function, potassium, glucose)

— Lipid panel

— HbA1c if risk factors

— Total testosterone and estradiol (baseline)

— Prolactin before estradiol initiation

— LFTs — baseline before oral estrogens

— Pregnancy test if patient has a uterus and any possibility of pregnancy

— STI screening per CDC guidelines based on sexual practices

— At 3 months and 6 months after initiation/dose change, then every 6–12 months

— Levels drawn at trough (just before next dose) for IM testosterone, midway between injections if using estradiol valerate IM

— Transdermal/oral steady-state: draw any time after stable dosing

— Feminizing: estradiol 100–200 pg/mL, testosterone <50 ng/dL

— Masculinizing: total testosterone 400–700 ng/dL

— Hct/Hgb every 3–6 months on testosterone × first year, then annually — stop or reduce dose if Hct >54%

— Potassium if on spironolactone — at 1–2 weeks after start/titration, then with routine labs

— Lipids annually; glucose/HbA1c annually especially on testosterone (insulin resistance can worsen)

— Prolactin annually first 3 years on estradiol; obtain MRI if >100 ng/mL or persistently rising

Baseline labs before initiating GAHT (Endocrine Society 2017 / UCSF):

Ongoing monitoring cadence:

Target levels:

Specific surveillance:

Step 3 management: A transgender man at 6-month follow-up has Hct 55% on weekly testosterone 100 mg SC — reduce dose, recheck in 6–8 weeks, screen for OSA, ensure hydration, hold smoking. Therapeutic phlebotomy if persistent.

Board pearl: Sex-specific reference ranges on lab reports may mislead — interpret CBC, creatinine, and PSA based on hormonal milieu and organs present, not the gender marker.

Diagnostic Workup — Advanced and Confirmatory Studies

— Persistent hyperprolactinemia (>100 ng/mL or rising) on estradiol → pituitary MRI to rule out prolactinoma (estrogens stimulate lactotrophs; small prolactinomas described)

— Hct >54% on testosterone → repeat after dose reduction; if persistent, evaluate for OSA (sleep study), polycythemia vera (JAK2), smoking cessation

— LFT elevation on oral estradiol → switch to transdermal; rule out viral hepatitis, NAFLD

— DEXA indicated if:

— Gonadectomy with hormone discontinuation or non-adherence

— Long-term GnRH agonist use without sex steroids

— Risk factors (low BMI, glucocorticoids, prior fracture)

— Use birth-sex reference database initially; some advocate affirmed-gender norms after years of GAHT — guidance evolving

— New chest pain on testosterone → standard ACS workup (ECG, troponin)

— Suspected VTE on estradiol → D-dimer, duplex US, CT-PA as indicated

— Consider thrombophilia screen only if provoked event with strong family history or recurrent VTE — not routine

— Breast cancer: transfeminine on estradiol ≥5 years → mammography every 2 years starting age 40–50 (low but increased risk)

— Transmasculine without mastectomy → standard female-range screening

— Cervical: per USPSTF if cervix present

— Prostate: PSA reference range is lower in transfeminine patients on estradiol; PSA >1 ng/mL may be concerning

— Transmasculine patients with breakthrough bleeding after sustained amenorrhea → transvaginal US, endometrial biopsy if >35 or risk factors

When monitoring labs are abnormal, escalate workup:

Bone health imaging:

Cardiovascular workup:

Cancer screening adjustments:

Endometrial evaluation:

Key distinction: Polycythemia from testosterone vs secondary erythrocytosis — always check for OSA, smoking, supraphysiologic dosing before labeling primary; Hct should normalize with dose reduction.

Board pearl: Routine thrombophilia screening before GAHT is NOT recommended — clinical risk stratification guides estradiol route selection.

Risk Stratification and Management Logic

— Withholding GAHT is rarely appropriate and may cause harm (depression, suicidality)

— High risk: age >40, smoker, BMI >30, prior VTE, thrombophilia, immobility, recent surgery

— Action: transdermal estradiol (no first-pass hepatic effect on clotting factors)

— Smoking cessation strongly recommended; some clinicians require it before oral estradiol

— Estradiol: lipid-neutral to favorable (HDL ↑, LDL ↓), modest BP-lowering

— Testosterone: ↓ HDL, ↑ LDL, ↑ Hct, may raise BP — screen and treat per ASCVD guidelines using calculator inputs reflecting current physiology

— Manage HTN, DM, dyslipidemia aggressively before/during therapy

— Adequate sex steroid levels protect bone; undertreatment is the main risk

— Post-gonadectomy: continuation of GAHT essential for bone preservation

— Screen for depression, anxiety, suicidality at each visit (PHQ-9, GAD-7)

— GAHT generally improves mental health outcomes

— Hold estradiol 2–4 weeks before major surgery (especially oral) to reduce VTE risk; transdermal may be continued in some centers

— Testosterone typically continued perioperatively

— Restart hormones after ambulation and VTE prophylaxis course

Pre-initiation risk stratification drives route and dose selection, not whether to treat

VTE risk (highest-yield):

Cardiovascular risk:

Bone health:

Mental health:

Perioperative management around gender-affirming surgery:

Step 3 management: A 45-year-old transfeminine smoker with BMI 32 wants to start estradiol — appropriate plan: counsel smoking cessation, start transdermal estradiol patch + spironolactone, baseline labs, follow-up at 3 months. Do not refuse therapy.

Board pearl: Route matters more than dose for VTE risk — transdermal estradiol does not significantly increase VTE; oral estradiol confers a 2–3× increased risk.

Pharmacotherapy — First-Line Regimens

— Estradiol options:

— Oral estradiol 2–6 mg/day (cheap, easy, but ↑VTE)

— Transdermal patch 0.025–0.2 mg twice weekly (preferred if VTE risk)

— Estradiol valerate IM 5–30 mg every 2 weeks, or cypionate 2–10 mg weekly

— Avoid ethinyl estradiol and conjugated equine estrogens — higher VTE risk and not measurable on assays

— Antiandrogens:

— Spironolactone 100–300 mg/day (most common in US) — monitor K+, BP

— GnRH agonist (leuprolide) — most effective, expensive; preferred in Europe

— Finasteride (5α-reductase inhibitor) — modest effect, mainly for hair

— Bicalutamide — hepatotoxicity risk, not first-line

— Progestins (medroxyprogesterone, micronized progesterone) — controversial; some patients report better breast development, mood; weigh against potential VTE/breast cancer/cardiac risk

— Testosterone cypionate or enanthate IM/SC 50–100 mg weekly or 100–200 mg every 2 weeks

— Transdermal gel 50–100 mg/day (caution: skin transfer)

— Testosterone undecanoate IM every 10 weeks (boxed warning: pulmonary oil microembolism)

— Target trough total T 400–700 ng/dL

— Adjust based on levels + clinical response + side effects, not levels alone

— Increase gradually; full effects take 2–5 years

Feminizing GAHT:

Masculinizing GAHT:

Dose titration:

Step 3 management: Hyperkalemia (K+ 5.6) in a transfeminine patient on spironolactone 200 mg + lisinopril → reduce spironolactone, recheck K+ in 1 week, consider switching to GnRH agonist or finasteride if recurrent.

Board pearl: Spironolactone is not contraceptive and is teratogenic — counsel patients with functional ovaries about contraception if sexually active with sperm-producing partners.

Expanded Pharmacology — Adjuncts, Special Formulations, and Drug Interactions

— Spironolactone + ACEi/ARB/NSAIDs → hyperkalemia

— Estradiol + CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) → reduced estradiol levels; may need dose increase

— Testosterone + warfarin → enhanced anticoagulation, check INR

— Testosterone + insulin/oral hypoglycemics → may improve glycemic control, watch for hypoglycemia

— Oral → transdermal estradiol for VTE risk, smoking, age >40, migraine with aura, hypertriglyceridemia

— IM testosterone → SC testosterone (lower peaks, more stable levels, self-administration easier)

— Spironolactone → GnRH agonist if hyperkalemia, hypotension, or insufficient androgen suppression

— Antiandrogens can be discontinued after orchiectomy in transfeminine patients

— Estradiol dose may be reduced

— Testosterone must be continued lifelong after oophorectomy in transmasculine patients to prevent osteoporosis

— Sperm banking before estradiol/antiandrogen (spermatogenesis recovers variably)

— Oocyte/embryo cryopreservation before testosterone ideally; testosterone may need to be paused for ovarian stimulation

— GnRH agonists (leuprolide, histrelin) at Tanner 2 — reversible

— Add affirming hormones typically at age ~14–16 per individualized assessment

Drug interactions:

Formulation switches — common Step 3 scenarios:

Post-orchiectomy / post-oophorectomy:

Fertility preservation timing:

Pubertal suppression (adolescents):

Step 3 management: A 38-year-old transfeminine patient on oral estradiol develops a migraine with aura — discontinue oral estradiol, switch to transdermal, document VTE/stroke risk-mitigation rationale.

CCS pearl: When changing estradiol route, recheck estradiol level at 6–8 weeks to confirm therapeutic range before next routine visit.

Special Populations — Elderly and Renal/Hepatic Impairment

— Cardiovascular risk dominates — prefer transdermal estradiol, avoid supraphysiologic testosterone

— Reassess goals: many patients reduce doses after years of stable feminization/masculinization while maintaining bone-protective levels

— Do not stop GAHT at arbitrary ages — continued therapy preserves bone, sexual function, mental health

— Screen for cancers per organs present; mammography for transfeminine on long-term estradiol

— Spironolactone contraindicated if eGFR <30 or hyperkalemia → switch to GnRH agonist or finasteride

— Adjust dosing of any renally cleared adjuncts

— Testosterone may improve erythropoiesis in CKD anemia — monitor Hct closely as polycythemia risk is higher

— Avoid oral estradiol — first-pass metabolism worsens cholestasis, raises clotting factors

— Transdermal estradiol preferred; bypasses liver

— Avoid bicalutamide (hepatotoxic)

— Testosterone IM/transdermal generally safe in mild disease; avoid 17α-alkylated oral androgens (methyltestosterone)

— Prior MI/stroke: transdermal estradiol; control BP, LDL <70 if ASCVD

— Heart failure: caution with testosterone (fluid retention, erythrocytosis)

— Atrial fibrillation on anticoagulation: monitor INR with testosterone

— Hormone-sensitive breast cancer history → individualized; often avoid estradiol or use lowest effective dose with oncology input

— Prostate cancer history in transfeminine patient → coordinate with urology; estradiol may be permissible after definitive treatment

Older adults (>50–60) on GAHT:

Renal impairment:

Hepatic impairment:

Cardiovascular comorbidity:

Cancer survivors:

Board pearl: Continuing GAHT into older age is safer than abrupt withdrawal — withdrawal causes hot flashes, mood destabilization, accelerated bone loss, and may worsen dysphoria.

Step 3 management: Transfeminine patient with eGFR 28 and K+ 5.4 on spironolactone — stop spironolactone, start GnRH agonist or finasteride, continue transdermal estradiol.

Special Populations — Pregnancy, Adolescents, and Other Subgroups

— Testosterone is teratogenic (genital virilization of XX fetus) — Category X

— Amenorrhea on testosterone does not equal infertility — ovulation can occur

— Contraception counseling is mandatory if uterus + ovaries retained and sperm exposure possible

— Options: IUD (copper or progestin), progestin implant, progestin-only pills (avoid combined estrogen-containing if continuing masculinization)

— If pregnancy desired: stop testosterone, menses typically return in 1–6 months

— During pregnancy/lactation: testosterone discontinued; resume after weaning

— Tanner 2 onset → consider GnRH agonist (puberty blocker) — reversible

— Affirming hormones at developmentally appropriate age after multidisciplinary assessment

— Bone density monitoring important during pubertal suppression

— Mental health support, family involvement, informed assent/consent per state law

— Chestfeeding/breastfeeding possible; testosterone not recommended during lactation (transfers in milk, suppresses supply)

— Restart testosterone after weaning

— Sperm banking before initiating estradiol/antiandrogens — spermatogenesis may not recover

— No major contraindication; monitor drug interactions with ART (especially cobicistat, ritonavir, which may alter estradiol levels)

— PrEP recommended based on risk; tenofovir + emtricitabine compatible with GAHT

Pregnancy potential in transmasculine patients:

Adolescents (Step 3 may test general principles):

Postpartum transmasculine patient:

Transfeminine patients and reproduction:

HIV and GAHT:

Step 3 management: A 27-year-old transmasculine patient on testosterone with amenorrhea × 18 months presents with nausea — order pregnancy test before any imaging or medications; positive test → stop testosterone immediately, obstetric referral.

Board pearl: Amenorrhea ≠ contraception in transmasculine patients on testosterone — this is one of the most-tested teaching points.

Complications and Adverse Outcomes

— VTE/PE — highest with oral estradiol, smokers, obesity; absolute risk still low but several-fold increased

— Hyperprolactinemia / prolactinoma — monitor prolactin; rare clinically significant tumors

— Hypertriglyceridemia — oral estrogens; switch to transdermal

— Cholelithiasis / cholestasis — oral estrogens

— Breast cancer — small absolute increase after 5+ years of estradiol; still lower than cisgender women

— Hyperkalemia (spironolactone), orthostatic hypotension (spironolactone), gynecomastia is desired but tenderness can be severe

— Mood changes — both improvement and lability reported

— Erectile dysfunction, decreased libido — expected; problematic if distressing

— Erythrocytosis (Hct >54%) — most common adverse lab finding; risk of thrombosis, stroke

— Acne, androgenetic alopecia

— Dyslipidemia — ↓HDL, ↑LDL, ↑TG

— Insulin resistance, weight gain, hypertension

— Sleep apnea — worsened or unmasked

— Vaginal atrophy, dyspareunia — topical estradiol can be used without reversing virilization

— Pelvic pain, ovarian cysts — usually benign

— Voice changes are permanent — counsel before initiation

— Mood: typically improved; rarely increased irritability

— Cardiovascular events — small increased risk, especially ischemic stroke and MI in transfeminine patients (FDA pharmacovigilance data)

— Bone loss if undertreated or post-gonadectomy off hormones

Feminizing GAHT complications:

Masculinizing GAHT complications:

Both:

Step 3 management: Transmasculine patient at 1 year, Hct 56%, BP 148/92, BMI 34 — decrease testosterone dose by 25%, screen for OSA with home sleep test, initiate antihypertensive, counsel weight management, recheck CBC/BP in 6 weeks.

Board pearl: Polycythemia is the #1 lab abnormality on testosterone — always check Hct at 3 and 6 months.

When to Escalate Care — Hospitalization and Specialist Consultation

— Suspected VTE/PE on estradiol → ED, imaging, anticoagulation; hold estradiol

— Acute MI or stroke → standard ACS/stroke pathways; hold hormones during acute event, restart with adjusted regimen

— Symptomatic hyperkalemia (K+ >6 or ECG changes) on spironolactone → ED management, stop spironolactone

— Pulmonary oil microembolism after testosterone undecanoate injection (cough, dyspnea, syncope minutes after IM dose) → ED observation

— Acute liver injury on oral estradiol or bicalutamide → admit, hepatology

— Endocrinology: complex regimens, persistent off-target levels, pituitary findings, fertility concerns

— Hematology: persistent Hct >54% despite dose reduction, recurrent VTE, thrombophilia

— Cardiology: ASCVD, atrial arrhythmia, heart failure on hormones

— Hepatology: persistent LFT elevation

— Mental health: suicidal ideation, gender dysphoria worsening, body-image distress

— Surgery: gender-affirming surgical planning, perioperative hormone management

— Do not stop GAHT during hospitalization unless contraindicated (acute VTE on estradiol, acute liver failure)

— Stopping causes withdrawal symptoms, hot flashes, mood destabilization, may worsen dysphoria

— Reconcile home GAHT on admission medication list — frequently missed

— Major surgery with high VTE risk → hold oral estradiol 2–4 weeks preop, transdermal often continued; coordinate with surgical team and VTE prophylaxis

— Testosterone usually continued

Emergency department / inpatient triggers:

Specialist consultation thresholds:

Inpatient hormone continuation:

Perioperative:

CCS pearl: On a CCS case with a hospitalized transgender patient, explicitly continue home GAHT (or document a hold reason) — it's a commonly missed reconciliation item that affects the score.

Board pearl: Never abruptly discontinue GAHT without a defined plan to resume — this is both a safety and dignity issue.

Key Differentials — Hormone-Related Mimics

— Hyperprolactinemia not due to estradiol:

— Medications: antipsychotics (risperidone, haloperidol), metoclopramide, opioids, verapamil

— Hypothyroidism (high TRH → prolactin)

— Pituitary adenoma (prolactinoma) independent of GAHT

— Stress, recent breast exam, exercise

— Polycythemia not from testosterone:

— Polycythemia vera (JAK2 mutation)

— Secondary: OSA, COPD, high-altitude, smoking, EPO-secreting tumors

— Hyperkalemia not from spironolactone:

— ACEi/ARB, NSAIDs, trimethoprim, renal insufficiency, adrenal insufficiency, rhabdomyolysis

— Gynecomastia/breast tenderness in transfeminine patient:

— Expected on estradiol; but unilateral mass → rule out breast cancer

— Drugs: spironolactone itself, antipsychotics, cimetidine

— Amenorrhea in transmasculine patient:

— Pregnancy (always rule out)

— Hyperprolactinemia, PCOS, thyroid disease, hypothalamic amenorrhea independent of testosterone

— Cortisol axis interpretation in GAHT — CBG affected by estradiol (raises total cortisol); use clinical context

— Thyroid function unchanged on standard GAHT

— Free vs total testosterone interpretation in transmasculine patients — SHBG affected by route and adjuncts

Same-category differentials (other endocrine/hormonal etiologies that mimic GAHT side effects):

Endocrine evaluation pitfalls:

Key distinction: Polycythemia vera vs testosterone-induced erythrocytosis — PV typically has leukocytosis, thrombocytosis, splenomegaly, JAK2 mutation; testosterone-induced is isolated red cell increase that improves with dose reduction.

Board pearl: Before attributing a finding to GAHT, rule out independent causes — a transmasculine patient with new HTN, headache, sweats on testosterone could still have a pheochromocytoma.

Key Differentials — Non-Hormonal Etiologies

— PE (estradiol-related VTE) — must rule out

— ACS — standard workup (ECG, troponin)

— Costochondritis from breast development

— GERD

— Anxiety/panic disorder

— Aortic dissection if hypertensive

— DVT — primary concern on oral estradiol

— Lymphedema, venous insufficiency, Baker cyst rupture, cellulitis, medication-induced edema (spironolactone rarely)

— Migraine (aura is a relative contraindication to oral estradiol)

— Prolactinoma (visual field defects)

— Idiopathic intracranial hypertension

— Cerebral venous sinus thrombosis (rare but estrogen-associated)

— Adjustment to changing body, social transition stress

— Major depressive disorder, bipolar disorder

— Hypothyroidism

— Substance use

— Subtherapeutic levels (check trough)

— Anemia (paradoxical — too aggressive phlebotomy)

— Sleep apnea (worsened by testosterone)

— Depression, hypothyroidism, iron deficiency

— Ectopic pregnancy (always rule out if uterus/ovaries present)

— Ovarian cyst, endometriosis, pelvic inflammatory disease

— Appendicitis, IBD — standard differential

— Subtherapeutic estradiol or testosterone (the affirming hormone)

— Menopause in transmasculine patients off hormones

— Carcinoid, pheochromocytoma (rare)

Chest pain in transfeminine patient on estradiol — differential:

Leg swelling:

Headache/visual symptoms on estradiol:

Mood changes:

Fatigue on testosterone:

Abdominal pain in transmasculine patient:

Hot flashes:

Step 3 management: Transmasculine patient with abdominal pain × 2 days, last menses 14 months ago, on testosterone — order beta-hCG before CT scan or pain medications; positive → pelvic US to evaluate for ectopic.

Board pearl: Always integrate organ inventory into differential — gender presentation does not exclude pregnancy, cervical pathology, or prostate disease.

Secondary Prevention and Long-Term Plan

— Calculate ASCVD risk; statin per AHA/ACC thresholds (LDL ≥190, DM with risk factors, 10-year risk ≥7.5–20%)

— Target BP <130/80; ACEi/ARB first-line, careful with spironolactone (additive K+)

— Smoking cessation — especially before/while on estradiol

— Aspirin only for established ASCVD per current guidelines

— Transdermal estradiol if any VTE risk factor

— Perioperative VTE prophylaxis (heparin, mechanical) for major surgeries

— Lifelong anticoagulation may not be needed after a single provoked VTE if oral estradiol stopped and switched to transdermal — individualize with hematology

— Adequate hormone levels (estradiol or testosterone) are the primary bone protection

— Calcium 1000–1200 mg/day, vitamin D 800–1000 IU/day

— DEXA per indications; bisphosphonates if osteoporosis

— Continue GAHT after gonadectomy lifelong

— Cervical (USPSTF) if cervix present

— Breast: transfeminine on ≥5 years estradiol → mammography q2 years 40–74; transmasculine without mastectomy → standard female screening; post-mastectomy → chest wall awareness, clinical exam

— Prostate: transfeminine — individualized discussion at 55, PSA cutoff lower due to estradiol suppression

— Colorectal, lung: per USPSTF regardless of gender

— Routine PHQ-9, GAD-7

— Maintain therapy access; address minority stress, family, employment issues

— Connect to community resources

Cardiovascular prevention:

VTE prevention:

Bone health:

Cancer screening (organ-based):

Mental health:

Step 3 management: At an annual visit for a 52-year-old transfeminine patient 8 years into estradiol: order mammogram, lipid panel, HbA1c, BP check, PSA discussion, DEXA if risk factors, depression screen, smoking cessation reinforcement.

Board pearl: "Anatomy-based screening, identity-based care" is the unifying principle.

Follow-Up, Monitoring Parameters, and Counseling

— Baseline → 3 months → 6 months → 12 months → every 6–12 months thereafter

— More frequent after dose changes, complications, or surgical events

— Symptoms (desired effects, side effects)

— Vitals (BP, HR, weight, BMI)

— Adherence and route satisfaction

— Mental health screen (PHQ-9, GAD-7, suicidality)

— Labs as indicated:

— Estradiol, testosterone (trough for IM/SC T; midway for IM E)

— CBC (Hct) for testosterone

— CMP (K+, LFTs, Cr)

— Lipids, glucose/HbA1c annually

— Prolactin annually × 3 years on estradiol

— Expected timeline of changes — manage expectations (full effects 2–5 years)

— Permanent vs reversible changes — voice deepening, clitoromegaly, scalp hair loss in transmasculine; breast growth in transfeminine

— Fertility implications — ongoing conversation, not one-time

— Contraception if applicable

— Sexual health and STI screening based on practices

— Safe injection technique for self-administered hormones; needle disposal

— UCSF Center of Excellence guidelines, Endocrine Society, WPATH SOC-8

— Peer-support communities, local LGBTQ+ health centers

— Provide bridge prescriptions when patients move or change insurance — interruptions cause withdrawal and dysphoria

— Send full records including dosing history, levels, surgical history

— Coordinate with surgical teams for perioperative hormone management

Visit cadence:

At each visit, monitor:

Counseling at each visit:

Patient education resources:

Transitions of care:

Step 3 management: At 3-month follow-up after starting estradiol/spironolactone: check estradiol level, testosterone level, K+, BP, weight, mood, satisfaction, adverse effects — adjust dose if levels outside target and symptoms suggest under/over-dosing.

CCS pearl: Schedule next visit and labs together in the orders — a common scoring item is appropriate follow-up interval (e.g., "return in 3 months with labs drawn 1 week prior").

Ethical, Legal, and Patient Safety Considerations

— Document discussion of benefits, risks, alternatives, unknowns specific to each regimen

— Address fertility preservation before initiation — failure to counsel is a documented ethical and medicolegal vulnerability

— Discuss permanence of certain changes (voice, clitoromegaly, breast tissue, scalp hair)

— Informed consent model is widely accepted; mental health letter not required for adults under SOC-8

— Assent + parental consent typically required; state laws vary — some restrict GAHT for minors

— Pubertal suppression is reversible; affirming hormones have semi-reversible/permanent effects

— Know your state laws (rapidly evolving)

— Protect gender identity information in EHR per patient preference

— Sex assigned at birth, current gender identity, organ inventory, pronouns should be documented separately

— Insurance billing may require legal name/sex — discuss with patient

— ACA Section 1557 prohibits sex discrimination including gender identity

— Document medical necessity for insurance appeals

— Provide letters for legal gender marker changes when requested

— Medication reconciliation across systems — GAHT is frequently dropped during hospital admissions, ED visits, or insurance changes

— Standardized handoffs to surgical and obstetric teams

— Avoid abrupt discontinuation

— Suicidality, intimate partner violence, child abuse — standard reporting obligations apply

— Do not report gender identity itself

— Acknowledge areas of evolving evidence (long-term cardiovascular outcomes, cancer risk) without conveying inappropriate uncertainty about treatment value

Informed consent:

Adolescents:

Confidentiality:

Discrimination and access:

Patient safety in transitions:

Mandatory reporting:

Research/equipoise:

Step 3 management: A 17-year-old established on testosterone for 2 years is admitted for appendectomy — continue testosterone perioperatively, use affirmed name/pronouns, document organ inventory for surgical team, ensure VTE prophylaxis. This is a transition-of-care safety scenario.

Board pearl: "Continue home GAHT unless contraindicated" — abrupt discontinuation is a patient safety event.

High-Yield Associations and Rapid-Fire Clinical Facts

Estradiol routes and VTE: oral > IM > transdermal (lowest)

Spironolactone: hyperkalemia, orthostasis, polyuria; teratogenic — counsel contraception

Target estradiol: 100–200 pg/mL; target T (feminizing): <50 ng/dL

Target testosterone (masculinizing): 400–700 ng/dL (trough)

Hct cutoff for action on testosterone: >54% → reduce dose, evaluate OSA

First lab abnormality on testosterone: erythrocytosis

First lab abnormality on spironolactone: hyperkalemia

Amenorrhea on testosterone typically by: 6 months

Voice deepening: 6–12 months, permanent

Breast growth on estradiol: starts 3–6 months, max at 2–3 years

Prolactin monitoring on estradiol: annual × 3 years; MRI if >100 ng/mL

Bicalutamide: avoid due to hepatotoxicity

Ethinyl estradiol / CEE: avoid — high VTE risk, unmeasurable

Testosterone undecanoate: pulmonary oil microembolism warning, in-office administration with observation

Migraine with aura on oral estradiol → switch to transdermal

Pregnancy test before any abdominal imaging in transmasculine patient with retained uterus/ovaries

Perioperative oral estradiol: hold 2–4 weeks before major surgery

Bone density: DEXA if gonadectomy + hormone gap, or risk factors

Cancer screening: organ-based, not gender-based

Mental health: GAHT improves outcomes; ongoing screening at each visit

Fertility counseling: must occur before hormone initiation

Continue GAHT during hospitalization unless specific contraindication

PSA: lower reference range on estradiol; >1 ng/mL may warrant evaluation

HRT in older adults: do not stop arbitrarily by age — preserve bone, mood, sexual function

Board pearl: The most-tested complications are VTE (oral estradiol), erythrocytosis (testosterone), and hyperkalemia (spironolactone) — memorize the management algorithm for each.

Board Question Stem Patterns

— 42-year-old transfeminine patient on oral estradiol 6 mg + spironolactone presents with unilateral calf swelling

— Best next step: duplex ultrasound; management: anticoagulation, switch oral → transdermal estradiol, continue gender-affirming care

— Distractor: "stop all hormones" — wrong; route change is preferred

— Transmasculine patient at 6 months, Hct 56%

— Action: reduce testosterone dose, screen OSA, recheck CBC in 6–8 weeks; therapeutic phlebotomy if persistent

— Patient on testosterone × 2 years, amenorrheic, now with nausea/abdominal pain

— First step: beta-hCG before imaging or medications

— Teaches: amenorrhea ≠ infertility

— Patient on spironolactone 200 mg + lisinopril, K+ 5.7

— Action: reduce/stop spironolactone, consider switch to GnRH agonist; recheck K+

— Transfeminine patient with prolactin 145 ng/mL, headaches, visual changes

— Next step: pituitary MRI

— Transfeminine patient on oral estradiol scheduled for vaginoplasty

— Action: hold oral estradiol 2–4 weeks preop, VTE prophylaxis, restart after ambulation

— 52-year-old transfeminine patient on estradiol × 8 years asking about screening

— Order: mammography every 2 years, lipids, HbA1c, BP, discuss PSA

— Transgender patient admitted for pneumonia; what to do with home GAHT?

— Action: continue home estradiol/testosterone; reconcile and document

— 14-year-old at Tanner 3 with persistent gender dysphoria

— Next step: multidisciplinary evaluation, consider GnRH agonist

Stem 1 — VTE on oral estradiol:

Stem 2 — Erythrocytosis on testosterone:

Stem 3 — Pregnancy in transmasculine patient:

Stem 4 — Hyperkalemia on spironolactone:

Stem 5 — Hyperprolactinemia:

Stem 6 — Perioperative management:

Stem 7 — Cancer screening:

Stem 8 — Hospitalization:

Stem 9 — Adolescent:

Board pearl: Step 3 stems frequently embed a transition-of-care or monitoring decision — pick the answer that continues affirming care while addressing the complication, not the one that stops therapy outright.

One-Line Recap

— Route-driven safety: oral estradiol → highest VTE risk; switch to transdermal for smokers, age >40, BMI >30, migraine with aura, prior VTE, or perioperative period

— Lab targets and triggers: estradiol 100–200 pg/mL, T <50 ng/dL (feminizing); T 400–700 ng/dL (masculinizing); Hct >54% → reduce testosterone; K+ elevated → reduce spironolactone; prolactin >100 → MRI

— Anatomy-based screening, identity-based care: cervical, breast, prostate, and pregnancy testing follow the organs present, not the gender marker; always rule out pregnancy in transmasculine patients with retained uterus/ovaries before imaging or medications

— Never abruptly stop GAHT: continue during hospitalization, perioperatively (with route modifications), and into older age; abrupt discontinuation causes withdrawal, accelerated bone loss, and worsening dysphoria — a safety event

Safe gender-affirming hormone therapy requires individualized regimen selection (route matters more than dose for VTE), structured monitoring at 3-6-12 months and then biannually, organ-based screening, and prompt management of route-specific complications — without abruptly discontinuing affirming care.

Top 4 recap bullets:

Single highest-yield Step 3 reflex: a transfeminine patient on oral estradiol with a new VTE risk factor or event → switch to transdermal, treat the complication, continue affirming care.

Single highest-yield monitoring reflex: at every GAHT visit, check the affirming hormone level, the relevant safety lab (Hct for T, K+ for spironolactone, LFTs/prolactin for estradiol), BP, weight, and mental health screen.

Board pearl: The right answer on Step 3 almost always modifies rather than discontinues gender-affirming hormone therapy.